Leukemias continue to cause signi®cant mortality in adults and children, and the use of standard cytotoxic chemotherapy has reached a therapeutic plateau. Thus, there is great interest in treatments directed against inappropriately activated cell signaling pathways which stimulate the uncontrolled growth of neoplastic cells. Increasing evidence suggests that the STAT signaling cascade may be one target of these therapies. Signal transducer and activator of transcription (STAT) proteins are critical in mediating the response of hematopoietic cells to a diverse spectrum of cytokines. Constitutive STAT activation is present in many malignancies and has been especially well characterized in acute and chronic leukemias. While STAT activation is a common characteristic of leukemias, the speci®c pattern of activated STATs and the manner by which STAT activation occurs vary with each disease. STAT tyrosine phosphorylation can occur through inappropriate Jak activation or by direct activation of an oncoprotein such as Bcr/Abl, and STAT serine phosphorylation may play an important role in leukemias as well. Thus, the STAT signaling pathway is an attractive target for therapeutic intervention, and strategies designed to inhibit STAT activation and STAT mediated gene transcription may play an important role in the next generation of anti-leukemia therapies. Oncogene (2000) 19, 2496 ± 2504.
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Human leukemias
Leukemias comprise a heterogeneous group of clonal hematologic malignancies which continue to cause signi®cant mortality and morbidity despite decades of research and drug development. Approximately 26 000 patients are diagnosed with leukemia in the United States annually, and more than 20 000 adults and children die each year of their disease (Holland et al., 1997) . Leukemias are classi®ed as acute or chronic, depending upon their clinical development and expected progression, and as lymphoid or myeloid, depending upon the lineage from which the cancer arises. The acute leukemias are characterized by a rapidly progressive, fatal course if untreated, but these diseases often respond to aggressive cytotoxic chemotherapy, especially in children and younger adults.
Acute lymphocytic leukemia (ALL) aects both children and adults, while acute myelogenous leukemia (AML) strikes predominantly adults. Although great strides in clinical response and long-term survival were initially achieved with the advent of chemotherapy in leukemia patients, particularly children, a plateau in clinical bene®t has been reached with the use of standard forms of cytotoxic chemotherapy alone.
In contrast to the rapidly progressive acute leukemias, the chronic leukemias are indolent, often asymptomatic, diseases in which median survivals often measure several years. However, the chronic leukemias cannot be cured by standard chemotherapy and are invariably fatal in the absence of bone marrow transplantation (BMT) (Lee et al., 1997; Rabinowe et al., 1993) . Chronic lymphocytic leukemia (CLL), the most common leukemia in the Western world, generally aects older patients with a median age of greater than 60 and is typically the most indolent leukemia (Rozman and Montserrat, 1995) . However, although chemotherapy can control CLL for periods of time, no cure has been identi®ed for CLL. Chronic myelogenous leukemia (CML) aects a slightly younger adult population (Sawyers, 1999) . Although CML cannot be cured by standard cytotoxic therapy, younger patients with an HLA-identical sibling or unrelated donor can undergo allogeneic BMT with the potential for long-term survival (Lee et al., 1997) .
Similarly, standard chemotherapy oers limited ecacy in the treatment of less common leukemias and hematologic malignancies. Myelodysplastic syndrome (MDS) includes a spectrum of bone marrow disorders characterized by ineective hematopoiesis and progression from anemia to eventual leukemic transformation (Heaney and Golde, 1999; Verwilghen and Boogaerts, 1987) . Likewise, standard therapy has achieved only limited success against chronic myelomonocytic leukemia (CMML) and myeloproliferative disorders such as polycythemia vera and essential thrombocythemia (Iland et al., 1995; Najean et al., 1994) . While the overproduction of erythrocytes or platelets can be controlled with marrow suppressive chemotherapy, the underlying disorder is not cured and often becomes refractory to treatment. Finally, combination chemotherapy has proven to be of little bene®t in the treatment of aggressive forms of adult T-cell leukemia (ATL). The clinical course of this heterogeneous leukemia depends upon the underlying biology and progression of the individual patient's disease, rather than upon any therapeutic interventions (Kawano et al., 1985) . Thus, a therapeutic plateau exists for standard therapy in many types of leukemias and hematologic malignancies.
Given the absence of a cure for chronic leukemias, and the therapeutic limits and toxicity of standard chemotherapy in acute leukemias, there has been great interest in biological agents and therapies directed against the molecular or cellular derangements in leukemia. By targeting inappropriately activated cell signaling pathways which stimulate the uncontrolled growth and survival of cancer cells, it may be possible to achieve an anticancer eect with minimal toxicity to normal cells and tissues. An example of such a compound is all-trans retinoic acid (ATRA), which is used to treat acute promyelocytic leukemia, a subtype of AML in which the retinoic acid receptor is expressed inappropriately due to a reciprocal translocation between chromosomes 15 and 17 (Tallman et al., 1997) . Recently, great attention has been focused upon initial clinical trials of the small molecule STI 571, which is directed against the Bcr/Abl tyrosine kinase present in CML (Thiesing et al., 1999) . One cell signaling pathway which may potentially serve as a target of such anticancer therapies is the STAT signaling pathway, which is inappropriately activated in many solid and hematologic tumors.
STAT signaling pathway
Signal transducer and activator of transcription (STAT) proteins play a crucial role in mediating the response of hematopoietic cells to a diverse spectrum of cytokines. STATs directly link cytokine receptor stimulation to gene transcription by acting as both cytosolic messengers and nuclear transcription factors. STATs reside in the cytoplasm of quiescent cells; cellular stimulation by a cytokine leads to phosphorylation of a conserved tyrosine residue (Darnell, 1997; Ihle, 1996; Leonard and O'Shea, 1998) . This phosphorylation can be catalyzed by Jak family kinases, intrinsic receptor tyrosine kinases and other cellular tyrosine kinases such as c-src. Once tyrosine phosphorylated, STAT proteins form dimers, translocate to the nucleus, and bind to speci®c DNA elements (Chen et al., 1998; Shuai et al., 1993 Shuai et al., , 1994 . In this elegant manner, STATs modulate the expression of target genes in response to cytokines. STATs can also be phosphorylated on unique serine residues (Wen et al., 1995; Zhang et al., 1995) . While not sucient for STAT activation and nuclear translocation, serine phosphorylation ampli®es the transcriptional activation mediated by tyrosine phosphorylation. This dual tyrosine and serine phosphorylation enables STATs to integrate signals from a variety of extracellular stimuli and intracellular signaling pathways (Frank, 1999) .
Re¯ecting the critical role of STATs in regulating cell growth and dierentiation, inappropriate STAT activation has been described in many solid and hematologic malignancies. Constitutive STAT activation has been especially well characterized in leukemias, and a growing body of evidence in both acute and chronic leukemias suggests that derangements in the STAT signaling pathway may be critical to the development of cancer in hematopoietic cells (CatlettFalcone et al., 1999; Frank et al., 1997; GouilleuxGruart et al., 1996; Nieborowska-Skorska et al., 1999; Weber-Nordt et al., 1996; Zhang et al., 1996) . The multitude of hematologic cancers which demonstrate abnormal STAT activation suggests that the STAT pathway may play an important role in the pathogenesis of malignancy and may serve as an attractive target of anti-cancer therapies.
Inappropriate STAT activation in leukemia
Drosophila studies Some of the initial studies implicating STAT activation in hematologic cancers were conducted in Drosophila, which express Jak and STAT homologues and which possess a primitive hematopoietic system. These reports demonstrated that inappropriate expression or mutational activation of the Jak homologue hop can lead to a leukemia-like hematopoietic proliferation. Luo et al. (1995) showed that the dominant, gain-of-function mutation hop Tum-1 results from a single amino acid substitution at residue 341 and produces a clonal plasmacyte overproliferation similar to human leukemias. Similar studies by Harrison et al. (1995) demonstrated that overexpression of wild-type hop or hop Tum-1 leads to an identical phenotype with tumor formation within the larval lymph glands, which serve as hematopoietic organs in Drosophila. The tumorigenicity of hop or hop Tum-1 overexpression was tissue speci®c, as expression in other tissues did not result in tumor formation. Hop overexpression was accompanied by tyrosine phosphorylation of the Jak homologue, suggesting that such phosphorylation may be important in the activation and tumorigenicity of hop. These ®ndings in Drosophila raised the possibility that the STAT signaling pathway might be similarly deranged in human hematologic malignancies.
Acute leukemias
In fact, constitutive activation of STAT1, STAT3 and STAT5 has been demonstrated in both acute and chronic leukemias, re¯ective of the broad spectrum of cytokines which activate these STAT family members physiologically (Table 1) . STAT1, STAT3 and STAT5 mediate cellular responses to a diverse range of growth factors, whereas STAT2, STAT4 and STAT6 are activated by a much more limited number of cytokines (Frank, 1999) . Numerous authors have reported inappropriate STAT activation in primary leukemia cells, although the speci®c patterns of STAT activation have been similar but not identical. In addition, the exact pro®le of STAT activation appears to depend (1996) , using probes for the FCgR1, b-casein and Bcl-2 promoters, revealed similar, but not identical, patterns of STAT activation in fresh and frozen primary cells from patients with AML, T-cell ALL and B-cell ALL. Constitutive STAT5 activation was seen in three of ®ve T-cell ALL and 12 of 19 B-cell ALL patients, while one of three B-cell ALL patients exhibited abnormal STAT1 activation. Of 14 AML patients in this study, ten showed inappropriate STAT1 activation, ten demonstrated constitutive activation of STAT3, and only one had STAT5 activation. STAT activation was also examined in several hematopoietic cell lines. Constitutive activation of STAT5 was found in the CML cell line K562, whereas all four Epstein-Barr virus (EBV) positive and interleukin (IL)-10-producing lymphoblastic and Burkitt's lymphoma (BL) cell lines exhibited abnormal STAT1 and STAT3, but not STAT5, activation. In contrast, two of two EBV-and IL-10-negative BL lines demonstrated no activation of STAT1, STAT3 or STAT5.
The largest study of primary cells of AML patients was published by Xia et al. (1998) , who examined primary bone marrow cells from 36 newly diagnosed AML patients. Twenty-®ve of the 36 patients had de novo AML, whereas 11 had developed secondary leukemia. EMSA using probes for the sis-inducible element (SIE), and for TB2, were used to detect activation of STAT1 and STAT3, and of STAT5, respectively. Inappropriate STAT3 activation was seen in ten patients (28%), while eight patients (22%) exhibited constitutive STAT5 activation. Four patients (11%) demonstrated activation of both STAT3 and STAT5, while ten patients exhibited activation of only one of the two STAT proteins. Of interest, Western blot analysis showed detectable STAT5B in 21 of 27 patients (78%), whereas STAT5A was not seen in any of 27 tested patients.
These studies show that the patterns of STAT activation are dierent in primary ALL and AML cells. Constitutive activation of STAT5 is most prevalent in T-cell and B-cell ALL. In addition, STAT1 activation is present in a minority of ALL patients, although STAT1 activation has not been studied as extensively. In contrast, inappropriate activation of STAT3 has been demonstrated most consistently in AML patients, although STAT1 and STAT5 have both been shown to be activated as well. These ®ndings suggest that the STAT proteins which are abnormally activated in cancer need not necessarily be the predominant STAT members activated in response to cytokines in normal cells of that lineage. For example, while IL-2 activates STAT1, STAT3 and STAT5, and IL-6 activates STAT1 and STAT3, but not STAT5, in lymphocytes, STAT5 is the most commonly activated STAT member in ALL cells. Similarly, while IL-3 and GM-CSF induce activation of STAT1 and STAT5 in myeloid cells, STAT3 activation is the predominant abnormality in AML cells. Since the STAT proteins activated in leukemia cells and their normal counterparts are dierent, it may be possible to target the individual STAT proteins which are activated in leukemia cells without inhibiting those STAT members needed for normal signal transduction in benign hematopoietic cells. Thus, the pharmacologic inhibition of individual STAT proteins in cancer cells may be possible with acceptable toxicity to normal cells.
It is also interesting that results have varied signi®cantly from individual study to study, and the discrepancies among published reports may be due to several factors. First, signi®cant dierences may exist in the patient populations under study, particularly with AML, which may be classi®ed under eight dierent subtypes and which may be primary or secondary in origin (Holland et al., 1997) . These dierent forms of AML may have distinct etiologies and pathologic abnormalities. Secondly, the sources of primary cells are not identical in all studies; reports dier in their use of peripheral blood leukocytes or bone marrow cells, as well as in their use of fresh or frozen cells. Interestingly, Xia et al. (1998) reported the lowest prevalence of STAT activation despite the use of primary bone marrow, rather than peripheral blood, cells. Thirdly, while laboratory groups have all utilized EMSA and antibody supershift assays to demonstrate STAT activation and identify individual activated STAT proteins, they have employed dierent oligonucleotide probes and antibodies. These dierences in experimental reagents may account, at least in part, for the dierences in observed results. It should also be noted that the identity of the cellular tyrosine kinases involved in the inappropriate phosphorylation of STATs in acute leukemias has not been carefully examined, in contrast to published reports in other leukemias. The one major exception is Philadelphia chromosome positive ALL, in which the Bcr/Abl tyrosine kinase has been shown to directly phosphorylate STAT proteins; this will be discussed in greater detail in the following section.
Chronic myelogenous leukemia
Similar to the experience in acute leukemias, a growing body of evidence demonstrates the critical role of STAT5 in the pathogenesis of chronic myelogenous leukemia (CML). Carlesso et al. (1996) observed inappropriate STAT1 and STAT5 activation in the Philadelphia chromosome positive CML lines K562 and BV173. To examine the signi®cance of STAT activation in CML, the expression vector pGDp210 was transfected into IL-3-dependent Ba/F3, 32D and TF-1 cells. Expression of the Philadelphia chromosome gene product Bcr/Abl p210 relieved the dependence of these cells on IL-3 and induced constitutive tyrosine phosphorylation and activation of STAT1 and STAT5. This ®nding suggested that Bcr/Abl causes cellular transformation by activating the signaling pathway normally triggered by the physiologic growth factor for these cells. To further delineate the role of the Bcr/Abl tyrosine kinase, 32D cells were transfected with the temperature-sensitive Bcr/Abl mutant p210TS-1. Factor independence and tyrosine phosphorylation of STAT5 were seen at the permissive, but not the nonpermissive, temperature. Additionally, Jak kinase activity was not consistently observed, suggesting direct tyrosine phosphorylation and activation of STAT1 and STAT5 by Bcr/Abl. Similar studies by Ilaria and Van Etten (1996) using the same expression plasmid and Ba/F3 and FDC-P1 cell lines revealed primarily tyrosine phosphorylation and activation of STAT5, although less prominent STAT1 and STAT3 activation was also seen. The Bcr/ Abl-positive CML lines K562, KBM5 and EM2 all demonstrated constitutive STAT5 tyrosine phosphorylation, whereas no such activation was seen in the Bcr/Abl-negative leukemia cell lines HL-60, U937 and BJAB. Transfection experiments with temperaturesensitive p210 mutants con®rmed the requirement of the Bcr/Abl tyrosine kinase activity for phosphorylation and activation of STAT5. Only low level Jak tyrosine phosphorylation was observed, and Jak proteins did not co-immunoprecipitate with Bcr/Abl. In addition, expression of dominant-negative Jak2 mutants was unable to block the phosphorylation and activation of STAT5 by p210. These results again suggested that Bcr/Abl directly tyrosine phosphorylates and activates STAT5. Shuai et al. (1996) reported similar constitutive STAT5 activation in three Bcr/Abl-positive CML lines. Using retroviral expression of Bcr/Abl p185 or p210 in murine bone marrow cultures, the investigators induced constitutive STAT5 binding to a FCgR1 promoter probe. Transfection studies using Bcr/Abl mutants con®rmed the requirement of tyrosine kinase activity for phosphorylation and activation of STAT5. Mutants with intact tyrosine kinase activity exhibited a similar ability to activate STAT5 as wild-type transfectants. However, mutant K671R, which had lost its tyrosine kinase activity due to a single amino acid substitution, was unable to phosphorylate or activate STAT5. Transfection studies with a temperature-sensitive Bcr/Abl mutant showed a correlation between STAT5 activation and cytokine-independent cell survival and growth.
In addition to this growing evidence in transfectants and cell lines, STAT activation has been examined in primary CML and AML cells (Chai et al., 1997) . Neither of two CML patients exhibited constitutive STAT5 activation, although abnormal STAT1 activation was seen in one patient. In the second patient, STAT activation was observed, although no individual STAT protein was identi®ed by antibody supershift studies, suggesting the presence of a STAT5 isoform which could not be recognized by the STAT5 antibody used in this study. The single AML patient in this report exhibited inappropriate activation of STAT5, and Western blot analysis con®rmed the presence of Bcr/Abl in this patient.
The physical interaction of Bcr/Abl and STAT5 was further delineated by Nieborowska-Skorska et al. (1999) using retroviral expression of Bcr/Abl mutants in 32Dc13 cells. Speci®cally, single point and deletion mutations of the SH2 and SH3 domains were used to de®ne the necessity of these two domains for tyrosine phosphorylation and activation of STAT5 by Bcr/Abl. Mutation or deletion of either the SH2 or SH3 domain did not aect STAT5 activation. Similarly, single point mutations in both domains, or deletion of the SH3 domain with a concomitant point mutation in the SH2 domain, did not in¯uence STAT5 activation. In contrast, deletion of the SH2 domain accompanied by a point mutation in the SH3 domain abolished the ability of Bcr/Abl to activate STAT5, as did deletions of both the SH2 and SH3 domains. The critical role of STAT5 in maintaining the neoplastic state was demonstrated by the inability of STAT5-de®cient mutants to resist apoptosis in the setting of IL-3 and serum withdrawal. The constitutively active STAT5B-DAM mutant was able to rescue STAT5-de®cient Bcr/ Abl mutants from apoptosis, con®rming the protective eect of STAT5.
In a similar vein, studies by Sillaber et al. (2000, in press ) demonstrated that a truncated STAT5B protein could dimerize with endogenous STAT5 and inhibit STAT5-induced gene transcription and growth in Bcr/ Abl-expressing hematopoietic cells. Ba/F3 cells were co-transfected with vectors expressing Bcr/Abl p210 and DSTAT5, a truncated STAT5B protein lacking Tyr-699 and the transcription activation domain. DSTAT5 was placed under a tetracycline inducible promoter, and addition of doxycycline induced a 78 kDa DSTAT5 protein in selected clones. DSTAT5 co-immunoprecipitated with endogenous STAT5 and inhibited STAT5 activation. Using a reporter gene construct containing four STAT binding motifs upstream of a luciferase reporter gene, expression of DSTAT5 resulted in 58 ± 76% inhibition of STAT5-induced transcription. Similarly, DSTAT5 induced a 26 ± 52% inhibition of cell growth. Propidium iodide staining revealed the absence of cell cycle arrest, but annexin-V staining con®rmed decreased cell viability upon expression of DSTAT5. In addition, DSTAT5 expression resulted in greater cell sensitivity to cytotoxic agents such as hydroxyurea and cytarabine.
Finally, investigators have also examined the STAT phosphorylation and activation induced by the alternatively spliced p190 form of Bcr/Abl, which is generally seen only in ALL. Ilaria and Van Etten (1996) noted that, in contrast to the STAT5 activation induced by p210 in Ba/F3 and FDC-P1 transfectants, transfection and expression of the p190 form of Bcr/ Abl induced tyrosine phosphorylation and activation of STAT6. This is intriguing, given that IL-4, a major cytokine regulating lymphocyte function, is known to activate this STAT member. The pattern of STAT phosphorylation induced by Bcr/Abl p190 was also examined by Frank and Varticovski (1996) , who noted increased tyrosine phosphorylation and activation of STAT1 and STAT5 in Ba/F3 transfectants expressing Bcr/Abl p190, as compared with transfectants which expressed p210. These results suggest that the biological dierences seen between cells transformed with the p190 and p210 forms of Bcr/Abl may re¯ect qualitative and quantitative dierences in STAT activation mediated by these two molecules.
A unique association between Bcr/Abl and STATs was suggested by the ®nding that an antibody raised to the tyrosine phosphorylated form of STAT1 recognizes both Bcr/Abl p210 and p190 (Frank and Varticovski, 1996) . This raised the intriguing possibility that a phosphotyrosine residue on Bcr/Abl may possess homology to the conserved phosphotyrosine of STAT proteins. Tyr-177 of Bcr/Abl is known to be critical for binding of the adapter protein GRB2, which leads to ras activation and eventual MAP kinase activation, so the eect of mutating Tyr-177 was studied. Ba/F3 cells transfected with a vector expressing the Y177F mutant of Bcr/Abl exhibited decreased tyrosine phosphorylation and activation of STAT1 and STAT5, compared with transfectants expressing wild-type Bcr/Abl. These results suggest that phosphorylation of Tyr-177 may be important for the ability of Bcr/Abl to activate the STAT signaling pathway.
Although CML has proven to be extremely informative in understanding the role of inappropriate STAT signaling in leukemias, several unanswered questions remain. For example, it is clear that STAT5 activation is necessary for Bcr/Abl p210 to confer cytokine independence and protection against apoptosis in transformed CML cells. However, activation of STAT1 and STAT3 has been observed as well, and the biological signi®cance of their activation remains to be delineated. Similarly, the importance of STAT1, STAT5 and STAT6 in mediating the eects of Bcr/ Abl p190 needs to be further examined, given the ®ndings of the Van Etten and Frank groups (Frank and Varticovski, 1996; Ilaria and Van Etten, 1996) . Given that p210 is found in CML, whereas p190 is seen almost exclusively in ALL, the observed dierences in STAT activation between the two Bcr/Abl isoforms are interesting and may explain why p210 and p190 give rise to their respective diseases. More detailed studies in this area may provide further insight into the roles of individual STAT proteins in speci®c leukemias.
Chronic lymphocytic leukemia
Cytokine-induced STAT activation is a key mechanism by which genes involved in essential cellular functions such as growth and survival are regulated. One of the hallmarks of leukemic cells is the ability to survive and proliferate in the absence of cytokines or growth factors on which their normal counterparts depend. If STATs are critical mediators of cytokine-induced proliferation, then it is not surprising that constitutive STAT activation underlies the pathogenesis of rapidly growing leukemias. Chronic lymphocytic leukemia (CLL), one of the most common forms of leukemia, diers from acute leukemias in that it is characterized by the gradual accumulation of a clonal population of relatively well dierentiated B lymphocytes (Rozman and Montserrat, 1995) . Thus, it seemed likely that the signaling abnormalities present in this disease would dier from those seen in acute leukemias. In fact, no constitutive STAT activation was seen in CLL . Given that CLL cells are fairly similar to normal B cells, it was hypothesized that signaling abnormalities in CLL would be more subtle than those seen in other malignancies. Although tyrosine phosphorylation is essential for STAT activation, phosphorylation of speci®c serine residues modulates the transcriptional response mediated by that STAT. Since cytokines important for lymphocyte function, such as IL-2 and IL-6, activate both STAT1 and STAT3, the possibility was considered that inappropriate serine phosphorylation of these STATs might be present in CLL. While this would not lead to activation of STATs per se, it would amplify the transcriptional signal induced by a physiologic stimulus for STAT activation such as a cytokine. In this way, inappropriate STAT serine phosphorylation could lead to the gradual accumulation of B cells similar to what is seen clinically (Frank, 1999) .
Although the critical serine residue had been mapped for STAT1 and STAT3, the ability to discern phosphorylation of this site in primary B lymphocytes was hampered by the diculty in achieving metabolic labeling of these cells with 32 P. Thus, antibodies were generated which speci®cally recognized STAT1 or STAT3 phosphorylated on ser-727 of each protein.
Although each site contains the sequence pro-met-serpro, the surrounding sequences diverge, and the antibodies to ser-727-phosphorylated STAT1 and ser-727-STAT3 do not cross-react. Using these antibodies in immunoblots on extracts of primary peripheral blood lymphocytes, constitutive serine phosphorylation of STAT1 and STAT3 was found in all 23 CLL patients examined, but none of the normal controls . Furthermore, neither enriched peripheral blood B cells nor tonsilar CD5+ B cells contained STAT1 or STAT3 serine phosphorylation, suggesting that its presence in CLL is not a consequence of the abundance of CD5+ B cells present, but represents a consequence of the malignancy.
Several unanswered questions remain about the role of STAT serine phosphorylation in CLL. The ®rst is the identi®cation of the kinase which mediates these phosphorylation events. Evidence suggests that several serine-threonine kinases may be able to mediate phosphorylation of these sites, although which kinase is involved, and whether the same kinase is phosphorylating both sites, remain to be determined. In addition, although STAT serine phosphorylation had been shown to modulate STAT-mediated gene activation, it is unclear how the serine phosphorylation of STAT1 and STAT3 aects the biology of CLL cells, and whether the phosphorylation of STAT1 and STAT3 on ser-727 is critical for the pathogenesis of CLL, or represents an epi-phenomenon. The eect of speci®c interruption of these STAT pathways will help elucidate its role in this disease.
The ®nding of constitutive serine phosphorylation of STAT1 and STAT3 in all CLL patients examined raises the possibility of using this modi®cation as a novel diagnostic approach in the screening and monitoring of this malignancy. Using the phosphoser-727-speci®c antibodies, STAT1 and STAT3 serine phosphorylation can be detected in CLL cells by immunocytochemistry or¯ow cytometry (Figure 1 ). This may be a sensitive and speci®c tool to help in diagnosing and monitoring CLL and similar approaches may be useful in studying other leukemias as well.
Chronic myelomonocytic leukemia
Chronic myelomonocytic leukemia (CMML) is a myeloproliferative syndrome characterized by a clonal myeloid proliferation and frequent progression to AML. A subgroup of this disorder is characterized by the TEL-PDGFR tyrosine kinase fusion protein resulting from the t(5;12)(q33;p13) chromosomal translocation (Golub et al., 1994) . The fusion protein consists of the amino terminus of TEL, a member of the Ets family of transcription factors, fused to the transmembrane and cytoplasmic domains of the platelet derived growth factor receptor (PDGFR), which retains its tyrosine kinase activity. The amino terminus of TEL contains an oligomerization domain that causes dimerization of the fusion protein, thereby activating the PDGFR tyrosine kinase. Palmer et al. (1997) have shown that the TEL-PDGFR fusion protein activates STATs in Ba/ F3 cells transformed with the fusion protein. By Western analysis and EMSA, both STAT1 and STAT5 were found to be tyrosine phosphorylated and were able to form DNA binding complexes. The PDGFR kinase inhibitor CGP57148B inhibited STAT1 and STAT5 tyrosine phosphorylation, indicating that PDGFR kinase activity was required for STAT activation. Jak kinase family members were not activated in these cells, and the Jak inhibitor AG490 did not alter STAT activation, suggesting that STAT phosphorylation was not occurring indirectly through Jak activation. Providing further evidence for direct STAT phosphorylation by TEL-PDGFR, STAT5 became phosphorylated in COS cells transfected with STAT5 and the fusion protein, but not a kinase inactive mutant. Native PDGFR was only able to phosphorylate STAT5 weakly in Ba/F3 cells, suggesting that the fusion protein may display both qualitative and quantitative dierences in STAT phosphorylation compared to the PDGFR kinase. This represents an additional mechanism by which a distinct chromosomal translocation leads to a common pathway of inappropriate STAT activation.
Adult T-cell leukemia
The role of STAT activation has also been examined in adult T-cell leukemia (ATL), a malignancy which arises from transformation of CD4-positive T lymphocytes by the human T-cell lymphotropic virus I (HTLV-1) (Holland et al., 1997; Kawano et al., 1985) . T-cells, which normally require IL-2 for growth and survival, initially remain IL-2-dependent after HTLV-1 transformation but eventually become IL-2-independent. Using EMSA with probes for the FCgR1 promoter, Migone et al. (1995) demonstrated the presence of constitutively activated STAT complexes, containing tyrosine phosphorylated STAT3 and STAT5, in two HTLV-1-transformed T-cell lines. Although the lines were factor-independent, IL-2 induced increased STAT binding of the FCgR1 promoter probe, suggesting that the cells were still capable of transducing a growth signal from activated IL-2 receptors. In contrast, no constitutive STAT activation was observed in non-HTLV-1-transformed T-cell lines and IL-2-dependent cell lines. In addition, Jak1 and Jak3 were found to be constitutively phosphorylated in HTLV-1-transformed MT-2 cells, and IL-2 increased activation of these Jak family members. Furthermore, constitutive STAT and Jak3 activation was found to accompany the development of IL-2-independence in HTLV-1-infected cord blood lymphocytes. The presence of constitutive STAT3 and STAT5 phosphorylation in IL-2-independent HTLV-1-transformed T cells is consistent with the physiologic activation of these STATs by IL-2 in resting or activated T lymphocytes.
To further delineate the importance of the Jak-STAT pathway in HTLV-1 transformation, the role of tax, the transcriptional activator protein encoded by HTLV-1, has been examined. In tax-transformed mouse ®broblasts, as well as HTLV-1-transformed human T-cell lines, Xu et al. (1995) observed constitutive tyrosine phosphorylation of a 130 kDa protein. Further studies identi®ed Jak2 as the phosphorylated protein in tax-transformed mouse ®bro-blasts, while Jak3 was identi®ed as the 130 kDa protein in HTLV-1-transformed human T-cell lines. Interestingly, tax-transformed mouse ®broblasts were shown to secrete IL-6, and conditioned medium from these cells could induce proliferation and tyrosine phosphorylation of the 130 kDa protein in non-transformed cells. IL-6 neutralizing antibodies blocked the ability of conditioned medium to induce these eects, suggesting a possible autocrine role for IL-6 in HTLV-1 transformation.
In addition to these studies in HTLV-1-transformed cell lines, STAT activation has been examined in primary peripheral lymphocytes obtained from patients with ATL. Takemoto et al. (1997) employed EMSA, using a probe for the FCgR1 promoter, and immunoprecipitation studies to investigate inappropriate STAT activation in nine patients with acute ATL and three patients with chronic ATL. All 12 patients were HTLV-1-positive and had at least 60% peripheral leukemia cells. Eight of the 12 patients exhibited constitutive tyrosine phosphorylation and activation of STAT proteins. Abnormal STAT3 activation was found in four patients (33%), STAT5 activation was present in two patients (17%), and two patients (17%) possessed both STAT3 and STAT5 activation. Thus, in Figure 1 Phospho-STAT speci®c antibodies as diagnostic tools. The inappropriate phosphorylation of STATs on tyrosine and serine residues in leukemia can be detected by immunocytochemistry and¯ow cytometry using antibodies which speci®cally recognize these modi®cations. STAT1 phosphorylated on ser-727 can be detected in CLL cells (right) but not in normal peripheral blood lymphocytes (left). Immuno¯uorescence was performed using an antibody speci®c for serine-727 phosphorylated STAT1 and a¯uorescein-conjugated secondary antibody both primary ATL cells and HTLV-1-transformed cell lines, inappropriate STAT3 and STAT5 activation has been identi®ed, consistent with the IL-2 independence of these cells. In contrast to the direct tyrosine phosphorylation of STAT5 by Bcr/Abl in CML, Jak3 appears to play an important role in the constitutive STAT activation induced by HTLV-1 transformation in ATL. Therefore, while activation of the STAT signaling pathway appears to be a common characteristic of leukemias, this activation can occur via several mechanisms and is dependent upon the individual disease, as well as the individual STAT proteins which are involved.
Targeting STATs for anti-leukemic therapy
Abundant evidence exists to suggest that inappropriate STAT activation is a common endpoint in most forms of human leukemia. Although STAT activation alone may lead to cellular transformation in certain cellular backgrounds (Bromberg et al., 1999) , it is more likely that STAT activation is one of several abnormalities in leukemia cells. In either case, targeting STATs is an attractive strategy to inhibit leukemia cell survival and growth. Since evidence exists in a number of systems that the magnitude of STAT activation in neoplastic cells exceeds that seen under physiologic conditions, it may be possible to suciently inhibit STAT signaling to reverse neoplastic growth without causing undue toxicity to normal cells (Frank, 1999) . Furthermore, the relatively mild phenotypes seen in most STAT null mice provides further evidence that STAT inhibition can be achieved without widespread toxicity.
The multiple steps involved before a STAT activates its critical target genes suggest a number of potential strategies to inhibit STAT function in leukemia ( Figure  2 ). STATs can become activated through autocrine or paracrine stimulation by cytokines or growth factors. Thus, receptor antagonists or antibodies targeting cytokine receptors would be one potential strategy. This approach has proved useful with the development of antibodies to HER2/neu in breast cancer (Baselga et al., 1996) , and antibodies to IL-6 and the IL-6 receptor have been used successfully in patients with plasma cell leukemia (Klein et al., 1991) and in models of multiple myeloma .
In order for STATs to become activated, they require phosphorylation of their critical tyrosine residue. Thus, inhibiting the kinases which activate STATs is an attractive strategy for therapy. There is evidence that AG490, the small molecule inhibitor of Jak kinase, can speci®cally decrease Jak2 activation and inhibit growth of ALL cells in a mouse model without aecting normal cells (Meydan et al., 1996) . CGP57148B, a tyrosine kinase inhibitor, inhibits Bcr/ Abl, TEL-ABL and TEL-PDGFR tyrosine kinase activity and the growth of cells expressing these fusion proteins . In the presence of the inhibitor, STAT1 and STAT5 activation by the TEL-PDGFR is abolished. Additionally, Jak inhibitors are involved in repressing Jak activation after cytokine stimulation and are inducibly expressed in normal cells (Alexander et al., 1999; Marine et al., 1999) . These genes or proteins could conceivably be introduced into leukemic cells to abrogate Jak-mediated STAT activation. Although CLL cells do not show constitutive STAT tyrosine phosphorylation, inappropriate serine phosphorylation of STAT1 and STAT3 is present in this disease . Thus, the development of inhibitors of STAT serine kinases may also be a potentially bene®cial strategy in diseases such as CLL.
STATs are recruited to the activated, tyrosine phosphorylated receptor-kinase complex through their SH2 domains. In addition, after STATs become tyrosine phosphorylated, they dimerize through reciprocal SH2-phosphotyrosine interactions. Thus, small molecule SH2 inhibitors would be attractive anti-STAT agents, as they could disrupt STAT activation through two mechanisms: prevention of the recruitment of STATs to the receptor complex and prevention of the dimerization which is critical for nuclear translocation and DNA binding.
Direct depletion of a STAT from a cell would be another strategy to interrupt inappropriate activation of this pathway. For example, antisense technology has been used successfully to reduce STAT concentration within a cell. It was shown in vitro that reducing STAT1 levels caused a decrease in the mitogenic response to growth factors such as PDGF (Marra et al., 1996) . In addition to antisense approaches, other pharmacologic agents may be capable of speci®cally depleting STATs. For example,¯udarabine is the most active agent against CLL. As a purine analogue, it was postulated to act via incorporation into the DNA of dividing cells. CLL cells have a low proliferative fraction, and most are in the G0/G1 phase of cell cycle, making a DNA-directed mechanism unlikely. Further investigation led to the ®nding that¯udarabine causes a speci®c decrease in STAT1 mRNA and protein levels, which may underlie the anti-neoplastic and immunosuppressive eects of this drug (Frank et al., 1999) . Although the mechanism by which¯udar-abine exerts this eect is unknown, it suggests that (6), and functionally inactive dominant negative STATS (7). Open circles, phospho-serine residues; ®lled circles, phospho-tyrosine residues pharmacologic agents can be developed to deplete speci®c STATs.
Even after a STAT has become tyrosine phosphorylated and formed a dimer, it may still be possible to inhibit STAT DNA binding and, thus, block its biological eect. Agents which bind to the STAT DNA binding domain could abolish STAT mediated gene activation, even after phosphorylation has occurred. For example, it is possible to introduce into a cell`decoy' oligonucleotides, short stretches of double stranded DNA containing STAT binding elements. If present in sucient concentrations within a cell, such a decoy molecule could bind the activated STATs within a cell before they could bind to the promoter elements of target genes. This would prevent STAT mediated gene activation and provide potential therapeutic eects.
STATs can also be inhibited by dominant negative STAT constructs which lack the DNA binding domain or the transactivation domain. Such STATs can still form dimers with wild-type STATs within a cell, thereby rendering them functionally inactive. That such a strategy can be eective has been shown in several systems. Dominant negative STAT5 has been shown to inhibit the growth of K562 leukemic cells (de Groot et al., 1999) . In addition, gene therapy with a dominant negative STAT3 can suppress the growth of a murine melanoma in vivo (Niu et al., 1999) . This latter study also demonstrates the feasibility of introducing a vector containing a dominant inhibitory STAT construct into a tumor in a model system, thereby achieving expression and function in an animal. Furthermore, cell death occurred in a greater proportion of cells than were apparently transfected, raising the possibility of a`bystander' eect in achieving tumor kill, which may make this strategy even more attractive.
Conclusion
The elucidation of the STAT signal transduction pathway provided important insight into the mechanisms by which cytokines and growth factors exert their eects on cell growth and survival. The ®nding that leukemias utilize a variety of mechanisms to activate this pathway inappropriately suggests that it may be critical for leukemogenesis and, thus, may be an attractive target for therapeutic intervention. A number of strategies can be designated to prevent STAT activation and STAT mediated gene transcription in cells, and one or more of these may play an important role in the next generation of anti-leukemia therapies.
